Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper
- Resolution leadership team joined by world leading clinical hepatologist Elliot Tapper, MD, FAASLD, and EMERALD Chief Investigator Professor Jonathan Fallowfield
Edinburgh and London, UK, 27 August 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces that it will host a virtual R&D webinar on Wednesday 17th September 2025 at 2pm BST / 9am ET / 6am PT for investors, analysts and media.
